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Abstract: 
Bacterial toxins are the deadliest compounds on the planet; a single copy of a toxin is capable of 
compromising a host cell. Amplification of toxicity is typically achieved by enzymatically 
targeting signaling cascades or inhibiting vital host proteins/complexes present in relatively few 
copies. Due to its fundamental importance for a living cell, a major cytoskeletal protein, actin, is 
a common target of many toxins. However, due to the high abundance of actin in the cytosol it is 
not clear how actin-targeting toxins can achieve their high efficiency. One of such toxins produced 
by pathogenic strains of Vibrio cholerae, Vibrio vulnificus, and Aeromonas hydrophila, the actin 
crosslinking domain (ACD), catalyzes the formation of an amide bond between Lys-50 and Glu-
270 of actin monomers, resulting in the formation of actin oligomers, which are unable to function 
properly. It was believed that ACD toxicity stems from a slow failure of the cytoskeleton due to 
the gradual accumulation of non-functional actin oligomers. However, this mechanism can be 
effective only assuming intracellular delivery of high concentrations of ACD toxin, because the in 
vitro rate of ACD activity applied to cellular conditions suggests that a single ACD molecule 
would require over 6 months to crosslink half of all cytoplasmic actin. On the contrary, we found 
that to implement its cellular toxicity, ACD is not required to crosslink all actin in the cell: the 
integrity of intestinal cell monolayers is compromised dramatically when only a small fraction 
(<6%) of the total cellular actin is crosslinked. This suggests that ACD-crosslinked actin oligomers 
even at low doses are toxic to cells.  
Since actin-binding domains of some actin-regulatory proteins are organized in tandems, these 
proteins potentially can bind to actin oligomers with affinities higher than those for a G-actin 
monomer, due to multiple binding sites accessible on a single oligomer molecule. This would 
render these actin-regulatory proteins non-functional. Formins are one family of such proteins 
governing the actin cytoskeleton dynamics important for numerous cellular processes. The main 
functional domains of formins, formin homology domains 1 (FH1) and 2 (FH2), cooperate in 
nucleation and elongation of actin filaments. Our data indicate that formins preferentially bound 
to the crosslinked actin oligomers with abnormally high affinity in cell culture. We found that actin 
polymerization controlled by formins was inhibited by sub-nanomolar concentrations of actin 
oligomers. To investigate the mechanism of formin inhibition exerted by the ACD-crosslinked 
actin oligomers, we preformed total internal fluorescence reflection microscopy (TIRFM) to 
monitor actin polymerization at the individual filament level. In the presence of profilin, the 
oligomers caused reversible blocks of elongation of formin-controlled, but not formin-free, 
filaments. The persistence of the blocks, as well as the fraction of blocked filaments was dependent 
upon oligomer concentration as well as the length of the FH1 domains, suggesting that both FH1 
and FH2 domains of formin contribute to the inhibition in profilin-dependent and profilin-
independent manners, respectively. Mathematical modeling of polymerization in bulk (pyrene 
actin assays) and on a single filament level (TIRFM) revealed that the oligomers potently inhibit 
both nucleation and elongation steps of actin filament assembly controlled by formins. Therefore, 
our findings implicate that ACD employs a novel toxicity mechanism by converting cytoplasmic 
actin into highly toxic oligomers that specifically target key steps of actin dynamics. This implies 
that toxins can not only exploit existing signaling pathways but also initiate a new toxicity cascade 
with de novo produced crosslinked actin species as “second messengers.” ACD creates toxic 
derivatives of actin with a disruptive “gain-of-function” mode of operation. These new actin 
species bind with high affinity to formins and adversely affect both their nucleation and elongation. 
We propose that the seemingly straightforward original assumption that ACD acts by the 
accumulation of bulk amounts of nonfunctional actin is inaccurate or at least incomplete. The toxin 
can be highly efficient at very low concentrations by acting on formins and, potentially, other actin 
regulatory proteins. This finding calls for the careful reevaluation of mechanisms used by other 
actin related toxins, both of protein and small-molecule natures. 
 
Bacterial toxins are the deadliest compounds on Earth; a single copy of some toxins are 
sufficient to compromise or even kill a host (Tam & Lingwood, 2007). Typically, bacterial toxins 
amplify their toxicity by regulating the activity of signaling cascades (e.g. over activation of Rho-
GTPase signaling cascades by cholera and anthrax toxins (Young & Collier, 2007)) or by 
inactivation of low abundant, essential host complexes (e.g. inactivation of ribosomes by Shiga 
and diphtheria toxins (M. S. Lee, Koo, Jeong, & Tesh, 2016)). Bacterial must produce efficient 
toxins because i) the host immune system rapidly neutralizes bacteria and their toxins; ii) only a 
small amount of toxin-producing bacterial cells are present early upon infections; iii) host 
commensal bacteria prevent colonization. 
Due to its vital role in various cellular processes, actin is a common target of bacterial toxins 
(Barbieri, Riese, & Aktories, 2002). Actin-targeting toxins work through direct and indirect 
modifications of actin dynamics. Actin is found in a delicate equilibrium between monomeric (G-
actin) and filamentous (F-actin) states, which allows for the constant rearrangement of the host’s 
cytoskeleton. This equilibrium and rearrangement is regulated by a wide variety of actin regulatory 
proteins. However, direct modification of actin by bacterial toxins (i.e. ADP-ribosylation (Barth 
& Aktories, 2011), binding of SipA (Lilic et al., 2003), or nucleation of new filaments by VopL 
(Namgoong et al., 2011)), can shift this equilibrium in either direction, disrupting the host’s 
cytoskeleton. Additional, bacterial toxins effect this equilibrium by altering the normal state of 
signaling cascades that also control actin dynamics, such as covalent modifications of Rho-
GTPases (Lerm, Schmidt, & Aktories, 2000) and proteins the control the equilibrium (W. L. Lee, 
Grimes, & Robinson, 2015). 
Upon delivery to the cytoplasm of effected host cells, the actin crosslinking domain (ACD) is 
an actin-specific toxin that catalyzes the covalent cross-linking of Lysine-50 (K50) of one actin 
monomer, to Glutamate-270 (E-270) of another actin monomer through the formation of an amide 
peptide bond (Cordero, Kudryashov, Reisler, & Satchell, 2006; Fullner & Mekalanos, 2000). This 
cross-link leads to the formation of actin oligomers of various sizes (Cordero et al., 2006; 
Kudryashov, Cordero, Reisler, & Satchell, 2008; Kudryashov, Durer, et al., 2008). Typically, K50 
and E270 are located approximately 20 Å apart in F-
actin; however, the ACD-mediated cross-linking 
results in a cross-link that disrupts this F-actin inter-
subunit interface, making the actin oligomers non-
polymerizable (Kudryashov, Durer, et al., 2008). This 
lead to the previously accepted hypothesis that ACD 
toxicity is dependent upon the accumulation of bulk 
amounts of actin into non-functional oligomers and 
the compromising of the host cell’s cytoskeleton.  
However, actin is one of the most abundant 
proteins in a eukaryotic cell, with concentrations 
Figure 1: Integrity of cell monolayers is effected before 
a measureble about of actin is crosslinked. Addition of 
ACD to intestinal cell monolayers results in the drop of 
trans-epithelial electrical resistance before the accumlation 
of a substantial amount of actin oligomers (Adapted from 
Heisler et al., 2015).  
 
exceeding 100 µM (Pollard & Borisy, 2003). Using 
previously determined rates of in vitro ACD cross-
linking rates (Kudryashova, Kalda, & Kudryashov, 
2012), it would take over six months for a single copy of 
the ACD toxin to cross-link half the actin cytoskeleton. 
Typically, ACD is found in pathogenic, Gram-negative 
bacteria from the Vibrio and Aeromonas spp., which 
result in a compromised host rapidly after colonization of a bacterium. In agreement with this 
quickly compromised host cells, the integrity of intestinal cell monolayers (IEC-18 cell lines) was 
drastically effected when only a small fraction (~5%) of cellular actin was cross-linked (Figure 1; 
(Heisler et al., 2015)). 
We hypothesized that this drastic drop in resistance 
was due to the actin oligomers binding with high affinity 
to actin binding proteins and inhibiting their activity. In 
support of this hypothesis, the actin oligomers possess a 
unique combination of properties that are not found in F- 
or G-actin, but rather they contain properties of each state 
of actin. The oligomers are capable of still binding G-
actin binding proteins, like profilin (Cordero et al., 2006), 
but contain multiple binding sites, similar to F-actin 
(Figure 2; (Heisler et al., 2015)). This combination of 
properties would allow for multivalent binding of the 
oligomers to actin regulatory proteins with multiple actin 
 
Figure 2: Mechanism of formin inhibition by ACD-
crosslinked actin oligomers. The ACD-crosslinked 
oligomers can bind with abnormally high affinity to 
proteins with multiple G-actin binding sites (e.g. 
formins) due to a unique combination of properties 
(Adapted from Heisler, et al., 2015). 
 
Figure 3: Actin oligomer bind with to formin-
family of proteins with high affinity. SHA-actin 
pull-down. Lanes A: SHA-actin–transfected cells 
treated with inactive LFNACD (non–cross-linked 
actin). Lanes X: SHAactin–transfected cells treated 
with active LFNACD (cross-linked actin). Lanes C: 
Non-transfected untreated cells used as a negative 
control. NaCl and FA label fractions eluted from 
Strep-Tactin beads with 0.5 M NaCl and 
50%formamide, respectively. Samples were 
subjected to immunoblotting and probed with 
antibodies against hemagglutinin (HA) tag, actin, 
various formins, and profilin. (Adapted from Heisler 
et al., 2015) 
binding domains. The affinity (avidity) of 
the oligomers would be the results of 
simultaneous binding of multiple actin 
binding domains, making the affinity a 
multiple of each actin binding domain. 
We utilized the anthrax toxin delivery 
machinery (Milne, Blanke, Hanna, & 
Collier, 1995) to deliver ACD (LFNACD; (Cordero et al., 2006)) into HeLa cells which had been 
transfected with a double-tagged, Twin-Strep–tag II and hemagglutinin, actin (SHA-actin; a gift 
from T. Vitta and M. Vartiainen, University of Helsinki) and used these cells for a pull-down assay 
against cross-linked actin oligomers. Several proteins from the formin family of proteins, including 
DIAPH1, DIAPH2, DAAM1, and INF2, preferentially bound to the ACD–cross-linked actin 
oligomers (Figure 3). Formins are a major family of actin binding proteins involved in cell 
migration, cytokinesis, cell-to-cell contacts, mitochondrial fission, stress fiber stabilization, others 
 
Figure 4: Inhibition of formins results in loss of cell integrity. 
Addition of formin specific (SMIFH2) inhibitors, but not Arp2/3 (CK-
666) specific inhibitors, resulted in the same drop in electrical resistance 
as seen with the addition of  ACD (Adapted from Heisler, et al., 2015). 
 
Figure 5: Oligomer cause blocks of mDia1-mediated actin polymerization. mDia1(14PP)-mediated polymerization from profilin-actin 
complexes in the absence (top) and presence (bottom) of actin oligomers (A-Oligo) was monitored by TIRFM (adapted from Heisler et.al, 
2015). 
other vital cellular functions (Breitsprecher & Goode, 
2013). Formins are characterized by their two functional 
domains, formin homology domains 1 (FH1) and 2 
(FH2), which cooperate in the nucleation and elongation 
of actin filaments (Kovar, 2006). The noncovalent 
FH2/FH2 homodimer nucleates new filaments and 
remains processively attached to the barbed end, fast 
growing end of the filament while also protecting the filament from capping proteins (Moseley, 
Maiti, & Goode, 2006). Tandem poly-proline (PP) stretches within the FH1 domains bind actin-
profilin complexes and can accelerate elongation up to 10-fold (Kovar, Harris, Mahaffy, Higgs, & 
Pollard, 2006). To determine if the inhibition of formins could explain the loss the cell integrity, 
we used SMIFH2, a formin specific inhibitor (Rizvi et al., 2009), on cell monolayers. Similar to 
ACD, the small molecule inhibitor resulted in a similar drop in cell integrity, shortly after addition 
(Figure 4). 
To elucidate the mechanism of formin inhibition, we utilized constitutively active fragments 
of the mouse orthologs mDia1 and mDia2 (FH1-FH2 domain fragments). Using these constructs, 
we monitored actin polymerization at the single filament level by total internal reflection 
fluorescence (TIRF) microscopy. To visualize individual actin filaments and the formins attached 
 
Figure 6: Inhibition of mDia1-mediated actin 
polymerization. IC50 of oligomers determined by 
TIRFM as a percentage of stopped filaments (black) 
or growth rate inhibition (red curves; adapted from 
Heisler et.al, 2015). 
 
 
Figure 7: Effects of oligomers on polymerization of mDia2-
controlled filaments. OG-actin (green) polymerization in the presence 
of SNAP-tagged mDia2 (SNAP-549–mDia2; red) and PFN1 before and 
after the addition of oligomers (black arrow). Red arrowheads indicate 
SNAP-549–mDia2 attached to an actin filament; white arrowheads 
indicate a formin-free filament. The kymograph shows a stalled SNAP-
549–mDia2–controlled filament upon addition of oligomers (Adapted 
from Heisler, et al., 2015).  
to filaments, 33% of total actin monomers were labeled with Oregon-green (OG-actin). Individual 
molecules of mDia2 were visualized through the fusion of a SNAP-tag® domain (New England 
Biolabs) and subsequent labeling with SNAP-Surface 549. The addition of actin oligomers caused 
reversible blocks of mDia1- and mDia2-mediated actin polymerization in the presence of profilin 
(Figure 5 and 7). Formin-controlled filaments were identified by faster growth and their dimmer 
appearance than formin-free actin filaments (Kovar et al., 2006). The fraction of blocked mDia1-
mediated polymerizing filaments and the average growth rates depended on the concentration of 
actin oligomers and resulted in a median inhibitory concentration (IC50) of 1.2 ± 0.6 nM (Figure 
6). Also, we observed numerous stopped filaments that would begin to polymerize with rates 
characteristic of formin-controlled filament due to the likely dissociation of a formin-bound actin 
oligomer (Figure 5). We also confirmed the inhibition of mDia2, a formin with only two 
polyproline rich stretches in its FH1 domains. Likewise, the actin oligomers potently inhibited 
elongation of mDia2-controlled actin filaments (Figure 7), proving the oligomer’s inhibition of 
formins is not specific to mDia1. The inhibition was not as significant in the absence of profilin, 
but still resulted in measureable blocks of formin-controlled actin polymerization (Figure 6). The 
interaction of the oligomer with profilin and the 
polyproline stretches of FH1 domain is therefore 
not an absolute requirement; rather the oligomer-
profilin-polyproline interaction significantly 
amplifies the efficiency by contributing to the 
multisite binding of the oligomers. In agreement, 
the appKI for mDia2 (containing 2 polyproline 
stretches) was higher than that found for full length 
mDia1(14PP) (data can be found in figure 3 of 
Heisler et al, 2015).  
To further characterize the mechanism of 
inhibition, we utilized bulk pyrene actin 
 
Figure 8. Actin oligomers inhibit mDia1-controlled actin polymerization. Effects of actin oligomers (A-Oligo) on actin polymerization 
in the absence (A and B) or presence of mDia1(14PP) (C and D) and without (A and C) or with PFN1 (B and D). Fluorescence was 
normalized and expressed in percent of maximum polymerization (Adapted from Heisler, et al., 2015). 
. 
 
Figure 9: Inhibition of mDia1-mediated actin 
polymerization. Shortening of the mDia1-FH1 domain results 
in higher IC50 values due a decrease in multi-valent binding of 
the oligomers (Adapted from Heisler et al., 2015). 
polymerization assays. Polymerization of pyrene-labeled actin can be monitored by fluorescence 
methods because the incorporation of pyrene actin into an actin filament results in a greater than 
7 fold increase in pyrene’s fluorescence (Cooper, Walker, & Pollard, 1983). Initially, we tested the 
effects on spontaneous actin polymerization (in the absence of other polymerization-promoting 
proteins) and found that the oligomers only had a marginal effect on actin polymerization in the 
absence (Figure 8A) and presence of PFN1 (Figure 8B). In the absence of profilin, the mild 
acceleration of polymerization is likely do to the incorporation of a small amount of actin 
oligomers into the actin filament, which leads to the destabilization and severing of the filaments. 
In contrast, PFN1 precludes the incorporation of the oligomers into filaments and slows the overall 
rate of polymerization. However, the oligomers caused a potent inhibition of formin-mediated 
actin polymerization in the absence and presence of PFN1 (Figure 8 C, D). Measuring the tangent 
slope at 50% of maximum polymerization, and fitting it to an isotherm binding equation, we found 
inhibition constants that correlated with the results from single filament level experiments. The 
median inhibitory concentration of inhibition (IC50) was equal to 2.0 ± 0.2 nM and 4.8 ± 0.6 nM  
in the presence (Figure 9) and absence of PFN1 (additional data and equations can be found in 
figure 4E of Heisler et al, 2015).  
We also tested the effect of ACD-crosslinked actin dimers, the only species of oligomers that 
can be purified to homogeneity, and found that they bind to and inhibit mDia1-mediated actin 
polymerization but to a lower extent (data can be found in supplementary figure 5, F to H of Heisler 
et al, 2015). This suggests that the inhibition of formins is propagated by the multivalent interaction 
of oligomers with formin homology domains. 
To elucidate which formin homology domain was responsible for the observed inhibition, we 
generated truncation 
mutants of mDia1-FH1 
domain (Figure 9). 
Shortening of the FH1 
domain from 14 PP to 0PP 
(absence of an FH1 domain) 
reduced the inhibitory 
effects of the oligomers in 
the presence (Figure 9) and 
absence (data can be found 
in supplementary figure 6 of 
Heisler et al, 2015) of PFN1. The IC50 values plateau at ~30 and ~16 nM for mDia1(FH2) 
constructs in the presence and absence of PFN1, respectively. This suggests that actin oligomers 
can bind to, and inhibit, the FH1and FH2 domains of the formin family of proteins. 
 
 
Figure 10: Inhibition of formin activity. The inhibition of nucleation in the absence (A) and 
presence (B) of PFN1 in pryenyl-assays. Similarly, quantification of barbed ends in the presence 
(C) and absence (D) of PFN1 show that both domains play a role in inhibition. Error bars 
represent SEM, N=3; * - p<0.05 determined by Student’s t-test (Adapted from Heisler, et al., 
2015). 
A 
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To understand the role of the FH1 and FH2 domains in the inhibition of formins by the 
oligomers, we utilized kinetic modeling based on the known rates of actin polymerization in the 
absence and presence of profilin and formins (Courtemanche & Pollard, 2013; Kovar, 2006) as 
well as the experimentally determined rates from our TIRF experiments (Figure 5). We found that 
our data fit a model of inhibition where the actin oligomers inhibit formin-mediated nucleation by 
binding to free formin with dissociation constants of 0.8 and 5 nM in the presence and absence of 
PFN1 (data can be found in supplementary figure 8, D and E of Heisler et al., 2015). 
Experimentally, the inhibition of nucleation in the absence of PFN1 was also observed in pyrenyl-
actin (Figure 10, A and C) and TIRFM experiments (data can be found in supplementary figure 4, 
 
Figure 10: Modeling of actin filament nucleation and elongation in the presence of ACD-crosslinked actin oligomers.  
(Detailed explanations and parameter values used in the modeling are given in the model description in Heisler et al, 2015.) 
A) Elongation rates as a function of total PFN1 concentration at 1 µM of total actin (see equations in Heisler et al, 2015). B-E) Kinetically 
modeled (solid lines) vs experimental data (dotted lines) graphs of the effect of actin oligomer on actin polymerization. Experimental data 
corresponds to data shown in Figure 8 (Adapted from Heisler, et al., 2015). 
F and G, and figure 7, G and H of Heisler et al., 2015).  In the presence of profilin, nucleation by 
mDia1(14PP) cannot be separated from the rapid elongation of newly nucleated, mDia1(14PP)-
controlled filaments, and therefore, we used mDia1(0PP) to monitor the inhibition mechanism 
(Figure 10, B and D). To improve the accuracy of our model, we accounted for the severing of 
filaments due to the incorporation of the actin oligomer in absence of profilin (Kudryashov, Durer, 
et al., 2008). In the presence of profilin, the actin oligomers are precluded from polymerization, 
and do not affect the stability of filaments.   
Disruption of the actin cytoskeleton by altering host signaling pathways (e.g. Rho-GTPases 
(Lerm et al., 2000)) is not a new mechanism of toxicity for pathogenic bacteria (Aktories, Lang, 
Schwan, & Mannherz, 2011). However, we discovered a novel toxicity pathway by which ACD 
produces a new toxicity pathway. The de novo produced actin oligomers act as second messengers 
to target actin regulatory proteins. The unique combination of properties that the oligomers possess 
(Figure 2) bind with abnormally high affinity to formins, potently inhibiting both profilin 
dependent and independent manners. ACD takes host actin and converts it into toxic species with 
a disruptive gain-of-function property. Therefore, the previously understood mechanism of 
toxicity (passive accumulation of non-functional ACD-produced actin oligomers), is incomplete. 
Low concentration of the toxin can be efficient by taking a small amount of actin and converting 
it into secondary toxins that targets the low abundant, but essential protein, formins. This new 
finding of how an actin-specific toxin alters the cytoskeleton calls for a refreshed look at our 
understanding of the mechanism used by other actin altering toxins actually work.  
References: 
Aktories, K., Lang, A. E., Schwan, C., & Mannherz, H. G. (2011). Actin as target for modification by 
bacterial protein toxins. FEBS Journal, 278(23), 4526-4543. doi:10.1111/j.1742-
4658.2011.08113.x 
Barbieri, J. T., Riese, M. J., & Aktories, K. (2002). Bacterial toxins that modify the actin cytoskeleton. 
Annual Review of Cell and Developmental Biology, 18(1), 315-344. 
doi:10.1146/annurev.cellbio.18.012502.134748 
Barth, H., & Aktories, K. (2011). New insights into the mode of action of the actin ADP-ribosylating 
virulence factors Salmonella enterica SpvB and Clostridium botulinum C2 toxin. European 
Journal of Cell Biology, 90(11), 944-950. doi:10.1016/j.ejcb.2010.11.007 
Breitsprecher, D., & Goode, B. L. (2013). Formins at a glance. Journal of cell science, 126(Pt 1), 1-7. 
doi:10.1242/jcs.107250 
Cooper, J. A., Walker, S. B., & Pollard, T. D. (1983). Pyrene actin: documentation of the validity of a 
sensitive assay for actin polymerization. Journal of Muscle Research and Cell Motility, 4, 253-
262.  
Cordero, C. L., Kudryashov, D. S., Reisler, E., & Satchell, K. J. (2006). The Actin cross-linking domain 
of the Vibrio cholerae RTX toxin directly catalyzes the covalent cross-linking of actin. The 
Journal of biological chemistry, 281(43), 32366-32374. doi:10.1074/jbc.M605275200 
Courtemanche, N., & Pollard, T. D. (2013). Interaction of Profilin with the Barbed End of Actin 
Filaments. Biochemistry, 52(37), 6456-6466. doi:10.1021/bi400682n 
Fullner, K. J., & Mekalanos, J. J. (2000). In vivo covalent cross-linking of cellular actin by the Vibrio 
cholerae RTX toxin. The EMBO Journal, 19(20), 5213-5323.  
Heisler, D. B., Kudryashova, E., Grinevich, D. O., Suarez, C., Winkelman, J. D., Birukov, K. G., . . . 
Kudryashov, D. S. (2015). ACD toxin–produced actin oligomers poison formin-controlled actin 
polymerization. Science, 349(6247), 535-539.  
Kovar, D. R. (2006). Molecular details of formin-mediated actin assembly. Current opinion in cell 
biology, 18(1), 11-17. doi:10.1016/j.ceb.2005.12.011 
Kovar, D. R., Harris, E. S., Mahaffy, R., Higgs, H. N., & Pollard, T. D. (2006). Control of the assembly 
of ATP- and ADP-actin by formins and profilin. Cell, 124(2), 423-435. 
doi:10.1016/j.cell.2005.11.038 
Kudryashov, D. S., Cordero, C. L., Reisler, E., & Satchell, K. J. (2008). Characterization of the enzymatic 
activity of the actin cross-linking domain from the Vibrio cholerae MARTX Vc toxin. The 
Journal of biological chemistry, 283(1), 445-452. doi:10.1074/jbc.M703910200 
Kudryashov, D. S., Durer, Z. A., Ytterberg, A. J., Sawaya, M. R., Pashkov, I., Prochazkova, K., . . . 
Reisler, E. (2008). Connecting actin monomers by iso-peptide bond is a toxicity mechanism of 
the Vibrio cholerae MARTX toxin. Proceedings of the National Academy of Sciences of the 
United States of America, 105(47), 18537-18542. doi:10.1073/pnas.0808082105 
Kudryashova, E., Kalda, C., & Kudryashov, D. S. (2012). Glutamyl phosphate is an activated 
intermediate in actin crosslinking by actin crosslinking domain (ACD) toxin. PloS one, 7(9), 
e45721. doi:10.1371/journal.pone.0045721 
Lee, M. S., Koo, S., Jeong, D. G., & Tesh, V. L. (2016). Shiga Toxins as Multi-Functional Proteins: 
Induction of Host Cellular Stress Responses, Role in Pathogenesis and Therapeutic Applications. 
Toxins, 8(3). doi:10.3390/toxins8030077 
Lee, W. L., Grimes, J. M., & Robinson, R. C. (2015). Yersinia effector YopO uses actin as bait to 
phosphorylate proteins that regulate actin polymerization. Nature structural & molecular biology, 
22(3), 248-255. doi:10.1038/nsmb.2964 
Lerm, M., Schmidt, G., & Aktories, K. (2000). Bacterial protein toxins targeting Rho GTPases. FEMS 
Microbiol Lett, 1-6.  
Lilic, M., Galkin, V. E., Orlova, A., VanLoock, M. S., Egelman, E. H., & Stebbins, C. E. (2003). 
Salmonella SipA polymerizes actin by stapling filaments with nonglobular protein arms. Science, 
301(5641), 1918-1921. doi:10.1126/science.1088433 
Milne, J. C., Blanke, S. R., Hanna, P. C., & Collier, R. J. (1995). Protective antigen-binding domain of 
anthrax lethal factor mediates transiocation of a heterologous protein fused to its amino- or 
carboxy-terminus. Molecular Microbiology, 15(4), 661-666.  
Moseley, J. B., Maiti, S., & Goode, B. L. (2006). Formin Proteins: Purification and Measurement of 
Effects on Actin Assembly. 406, 215-234. doi:10.1016/s0076-6879(06)06016-2 
Namgoong, S., Boczkowska, M., Glista, M. J., Winkelman, J. D., Rebowski, G., Kovar, D. R., & 
Dominguez, R. (2011). Mechanism of actin filament nucleation by Vibrio VopL and implications 
for tandem W domain nucleation. Nature structural & molecular biology, 18(9), 1060-1067. 
doi:10.1038/nsmb.2109 
Pollard, T. D., & Borisy, G. G. (2003). Cellular Molitiy Drive by Assembly and Disassembly of Actin 
Filaments. Cell Press, 112, 453-465.  
Rizvi, S. A., Neidt, E. M., Cui, J., Feiger, Z., Skau, C. T., Gardel, M. L., . . . Kovar, D. R. (2009). 
Identification and characterization of a small molecule inhibitor of formin-mediated actin 
assembly. Chemistry & biology, 16(11), 1158-1168. doi:10.1016/j.chembiol.2009.10.006 
Tam, P. J., & Lingwood, C. A. (2007). Membrane cytosolic translocation of verotoxin A1 subunit in 
target cells. Microbiology, 153(8), 2700-2710. doi:10.1099/mic.0.2007/006858-0 
Young, J. A., & Collier, R. J. (2007). Anthrax toxin: receptor binding, internalization, pore formation, and 
translocation. Annual review of biochemistry, 76, 243-265. 
doi:10.1146/annurev.biochem.75.103004.142728 
 
